Gerald Maguire
Psychiatry · San Juan Capistraco, CANPI 1144300302
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,349,552 of the $1,829,658 with a category attached, or 73.8%. It is spread thinly across 20 manufacturers, the largest accounting for just 18.4%. 2025 is the largest year on record at $493,391, 2.3 times the $216,556 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,966 payments — averaging $930.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$336K
- Alkermes, Inc.$290K
- Otsuka America Pharmaceutical, Inc.$261K
- E.r. Squibb & Sons, L.L.C.$235K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$210K
- Axsome Therapeutics, Inc.$174K
- plus $324K from 14 others
Across 287 payments — averaging $16,631 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.5M
- Teva Pharmaceuticals USA, Inc.$1M
- AbbVie$1M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$558K
- Sumitomo Pharma America, Inc.$181K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145K
- plus $355K from 8 others
What the payments were for
- Consulting fees$268,05115%
- Speaking & faculty fees$1,349,55274%
- Travel & lodging$162,7379%
- Food & beverage$49,2583%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 367 | $336,325 |
| Alkermes, Inc. | 283 | $289,712 |
| Otsuka America Pharmaceutical, Inc. | 324 | $261,006 |
| E.r. Squibb & Sons, L.L.C. | 197 | $235,002 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 204 | $210,475 |
| Axsome Therapeutics, Inc. | 162 | $173,623 |
| Vanda Pharmaceuticals Inc. | 95 | $107,853 |
| Johnson & Johnson | 166 | $98,289 |
| Sunovion Pharmaceuticals Inc. | 100 | $66,002 |
| Teva Pharmaceuticals USA, Inc. | 15 | $21,030 |
| Acadia Pharmaceuticals Inc | 13 | $9,811 |
| Eisai Inc. | 5 | $8,385 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $6,068 |
| Sage Therapeutics, LLC | 4 | $2,818 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $2,684 |
| AbbVie(2 entities) | 8 | $303 |
| Biogen | 1 | $102 |
| Boehringer Ingelheim | 1 | $94 |
| Indivior Inc. | 2 | $42 |
| Novartis | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,137,583
- INGREZZA$324,379
- REXULTI$251,628
- CAPLYTA$207,721
- Auvelity$170,405
- COBENFY$163,550
- Fanapt$106,807
- SPRAVATO$94,606
- LATUDA$62,944
- AUSTEDO$19,743
- NUPLAZID$9,596
- Dayvigo$8,385
- ABILIFY MAINTENA$6,686
- TRINTELLIX$5,969
- UZEDY$1,111
- ARISTADA$904
- INVEGA SUSTENNA$265
- INVEGA TRINZA$265
- ABILIFY ASIMTUFII$242
How this compares
$1,829,658 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 24 | $6,602 |
| Lamotrigine | 30 | $397 |
| Buspirone Hcl | 20 | $327 |
| Quetiapine Fumarate | 27 | $302 |
| Clonazepam | 31 | $294 |
| Olanzapine | 18 | $288 |
| Gabapentin | 50 | $264 |
| Duloxetine Hcl | 12 | $249 |
| Trazodone Hcl | 29 | $218 |
| Bupropion Hcl SrBupropion Hcl | 11 | $172 |
| Pregabalin | 23 | $141 |
| Lorazepam | 19 | $123 |
| Doxepin Hcl | 13 | $85 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $85 |
| Divalproex Sodium | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Juan Capistraco
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
- Jason BermakSan Rafael$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.